H.C. Wainwright sets $18 target on NeuroPace stock with Buy rating

H.C. Wainwright initiated coverage of NeuroPace (NPCE) with a Buy rating and an $18 price target, citing the company's 22% revenue growth and the clinical effectiveness of its RNS system in treating drug-resistant focal epilepsy. This positive outlook is supported by strong Q1 2025 revenue of $22.5 million (up 24% YOY) and raised full-year guidance of $93-97 million, despite recent mixed results from the NAUTILUS study on idiopathic generalized epilepsy; management anticipates a CAGR of over 20% through 2027. Despite a recent price cut of 30% following the NAUTILUS study results, the analyst views this as an attractive entry point, as the data did not affect the RNS system’s strong sales momentum in patients with focal epilepsy.

Analysis

H.C. Wainwright has initiated coverage on NeuroPace Inc. (NASDAQ:NPCE) with a Buy rating and an $18.00 price target, underscoring the company's robust 22% year-over-year revenue growth in 2024 to $79.9 million and the clinical efficacy of its RNS system for drug-resistant focal epilepsy. This positive initiation aligns with a broader bullish analyst consensus, with price targets ranging from $15 to $20. NeuroPace demonstrated continued financial strength in Q1 2025, reporting $22.5 million in revenue, a 24% year-over-year increase, and has subsequently raised its full-year 2025 revenue guidance to $93-$97 million, indicating anticipated growth of 16-21%. Management projects a CAGR exceeding 20% through 2027, supported by strong fundamentals including impressive gross margins of 75% and a current ratio of 6.63. Despite the stock's 79% appreciation over the past year, outperforming the XBI's 11% decline, a recent 30% price reduction following the one-year NAUTILUS study data readout is viewed by H.C. Wainwright as an attractive entry point, as the study's mixed results for idiopathic generalized epilepsy (IGE) are not expected to impede the RNS system's sales momentum in its established focal epilepsy market. While the NAUTILUS study met its primary safety endpoint, it did not achieve statistical significance for primary effectiveness in the overall IGE population, though a subgroup analysis showed promise. NeuroPace intends to discuss these findings with the FDA for potential regulatory pathways. Other analysts, including Cantor Fitzgerald (Overweight) and Leerink Partners (Outperform), maintain positive ratings, acknowledging the strong financial performance despite the NAUTILUS outcome.

Key Decisions for Investors

• Investors may consider the recent 30% share price decline, attributed to the mixed NAUTILUS study results, as a strategic entry point given the sustained strong revenue growth from the RNS system in its core focal epilepsy market and positive analyst sentiment.
• Closely monitor NeuroPace's engagement with the FDA regarding the NAUTILUS study data, as successful navigation towards a targeted indication for Idiopathic Generalized Epilepsy could unlock further market opportunity, though the current investment thesis primarily rests on focal epilepsy.
• Evaluate the company's strong financial metrics, including a 75% gross margin, a 6.63 current ratio, and consistent double-digit revenue growth (24% YoY in Q1 2025, with 16-21% projected for FY25), which underpin its operational efficiency and growth trajectory.